New insulin formulations for use in insulin pumps
Incorporating antimicrobial excipients into insulin formulations addresses the issue of bacterial colonization in insulin pumps, enhancing catheter longevity and safety by inhibiting bacterial growth and biofilm formation, thus improving patient care and reducing costs.
Patent Information
- Application Number
- PCT/CA2025/050740
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-28
- Filing Date
- 2025-05-28
- Publication Date
- 2025-12-04
AI Technical Summary
Current insulin pumps face challenges with frequent catheter replacement due to bacterial colonization and infections, which are costly, unpleasant, and increase the risk of adverse events, while antibiotics are not viable for long-term use due to toxicity and antibiotic resistance.
Incorporation of antimicrobial excipients, such as metals (copper, zinc, nickel, and antioxidants like N-acetylcysteine) into insulin formulations to inhibit bacterial growth and biofilm formation on catheters, extending their use beyond the typical 2-3 days.
The antimicrobial excipients effectively prevent bacterial colonization and biofilm formation on catheters, potentially extending their use, improving patient safety, reducing costs, and minimizing environmental impact.